Charles River Laboratories and CEBINA announce strategic collaboration to accelerate cutting edge neuroscience research
- Charles River Laboratories and CEBINA GmbH have announced a strategic collaboration within the DanubeNeuro acceleration program.
- DanubeNeuro focuses on advancing pioneering academic research projects in neurodegeneration to create new drugs and innovative technologies.
- The collaboration will leverage CEBINA’s experience in acceleration programs and Charles River’s expertise in CNS drug discovery and development.
- The initiative aims to address major unmet medical needs in neurodegenerative disorders like Alzheimer’s and Parkinson’s.
Read more
Expert Systems expands operations in Europe to support drug discovery for neurodegenerative diseases with Polku Therapeutics
- Expert Systems is expanding its operations in Europe through a strategic collaboration with Polku Therapeutics.
- Polku Therapeutics focuses on developing treatments for neurodegenerative diseases like Parkinson's and Alzheimer's.
- Expert Systems will provide advanced computational tools and expertise to fast-track drug discovery.
- The collaboration aims to identify potential therapeutic targets and optimize candidate selection.
Read more
ImCheck receives FDA fast track designation for ICT01 in combination with azacitidine and venetoclax in first-line acute myeloid leukemia for patients unfit for induction chemotherapy treatment
- ICT01, a humanized anti-butyrophilin 3A monoclonal antibody, has shown encouraging clinical data in AML in its ongoing Phase 1/2a EVICTION study.
- The FDA granted Fast Track designation to ICT01 in combination with azacitidine and venetoclax for AML patients 75 years or older, or those with comorbidities precluding standard intensive induction chemotherapy.
- The EVICTION study includes a randomized dose-optimization cohort evaluating two doses of ICT01 in combination with azacitidine and venetoclax.
- Emerging data showed reproducible activation and migration of γ9δ2 T cells, suggesting effective target engagement and observed efficacy.
Read more
Oxford Brain Diagnostics and Memory Treatment Centers establish research collaboration to explore Alzheimer's disease
- Oxford Brain Diagnostics and Memory Treatment Centers have initiated a research collaboration.
- The project will use Cortical Disarray Measurement (CDM) to assess brain regions affected by neurodegenerative conditions.
- The study will focus on subjects who are cognitively impaired and receiving anti-amyloid treatment.
- Insights from this project will be shared in a research publication.
Read more
Anokion announces new data from the phase 1 MoveS-it study supporting ANK-700 for relapsing-remitting multiple sclerosis
- Anokion presented new data at the 40th Congress of ECTRIMS in Copenhagen, Denmark.
- The Phase 1 MoveS-it study evaluated the safety and tolerability of ANK-700 in 34 patients with RRMS.
- ANK-700 showed no Serious Adverse Events (SAEs) and no evidence of disease exacerbation.
- Pre-clinical data demonstrated the potential of ANK-700 in expanding antigen-specific regulatory T-cells.
Read more
New Alzheon peer-reviewed scientific publication describes study design and baseline characteristics from APOLLOE4 Phase 3 trial of oral ALZ-801/valiltramiprosate in APOE4/4 homozygous individuals with early Alzheimer’s disease
- Alzheon, Inc. announced a new scientific publication on the APOLLOE4 Phase 3 study, focusing on APOE4/4 homozygotes with early Alzheimer's disease.
- The study is the first Phase 3 trial targeting this high-risk population, who have a significantly higher risk and earlier onset of Alzheimer's.
- The 78-week trial is randomized, double-blind, placebo-controlled, and includes 325 subjects aged 50-80 years.
- Topline data from the trial is expected in late 2024, with a focus on evaluating the efficacy and safety of ALZ-801.
Read more
Ferrer advances research into progressive supranuclear palsy (PSP) with the inclusion of the first participant in a phase II clinical trial
- Ferrer has dosed the first participant in the Phase II PROSPER clinical trial for PSP.
- The trial will evaluate the safety and efficacy of FNP-223, a novel therapy aimed at slowing PSP progression.
- PROSPER is a randomized, double-blind, placebo-controlled trial with a 52-week treatment period and a 4-week follow-up.
- The study will include up to 220 participants across 46 sites in the US, UK, and 7 EU countries.
Read more
Breakthrough in long COVID: an investigator-initiated trial with Hyundai Bioscience's Xafty by UCSD
- Hyundai Bioscience has signed an MOU with UCSD to conduct an investigator-initiated trial for Xafty, a niclosamide-based antiviral, to treat Long-COVID.
- The trial will be led by UCSD Professor Ajay Bharti, an expert in the neurocognitive effects of viral illnesses.
- Xafty has shown promise in previous trials, meeting FDA's primary endpoints and demonstrating faster symptom improvement in high-risk COVID-19 groups.
- The trial aims to confirm Xafty's ability to address Long-COVID symptoms through multiple mechanisms, including virus suppression, inflammation inhibition, and neuroprotection.
Read more
Immunic presents key vidofludimus calcium data at the 40th congress of ECTRIMS, highlighting its therapeutic potential in multiple sclerosis
- Vidofludimus calcium reduced neurofilament light chain levels in the Phase 2 CALLIPER trial for progressive multiple sclerosis.
- Preclinical data showed improved neuronal survival and reduced development of pathogenic peripheral T helper cells.
- Vidofludimus calcium may reduce fatigue in multiple sclerosis patients by preventing Epstein-Barr virus reactivation.
- Next major data readout for vidofludimus calcium is expected in April 2025 from the CALLIPER trial.
Read more
Senhwa Biosciences submits IND to US FDA for pidnarulex pilot study in advanced solid tumors
- Senhwa Biosciences has submitted an IND application for Pidnarulex to the US FDA.
- The pilot study, sponsored by the NCI, will focus on pharmacodynamics in patients with advanced solid tumors.
- Future trials may explore Pidnarulex in combination with immunotherapy, ADCs, and PARP inhibitors.
- The study aims to investigate biomarker responses to Pidnarulex in patients with or without homologous recombination deficiency (HRD).
Read more
